Subjects requiring systemic steroid therapy should be receiving ?  mg/day of prednisone (or equivalent) for the  weeks preceding start of study.
Ongoing chronic systemic steroid therapy required (> mg oral prednisone daily or equivalent)
Patients requiring chronic treatment with systemic steroid therapy, other than replacement dose steroids in the setting of adrenal insufficiency or treatment with low, stable dose of steroid (<mg/ day prednisone or equivalent) for stable CNS metastatic disease.
On chronic systemic steroid therapy (> mg/day prednisone or equivalent) within  weeks prior to first dose of study drug or on any other form of immunosuppressive medication
Current systemic steroid therapy other than physiologic replacement (i.e. prednisone ?  mg or equivalent). Inhaled or topical steroid use is allowed.
Evidence of clinically significant immunosuppression such as the following:\r\n* Primary immunodeficiency state such as severe combined immunodeficiency disease\r\n* Concurrent opportunistic infection\r\n* Receiving systemic immunosuppressive therapy (>  weeks) including oral steroid doses >  mg/day of prednisone or equivalent within  months prior to enrollment; (steroids for pre-medication for imaging studies are allowed).
Patient receives chronic steroid use >  mg prednisone (or steroid equivalent) daily
Patients requiring systemic steroid therapy or any immunosuppressive therapy (?mg/day prednisone or equivalent) which cannot be discontinued at least  days prior to first dose of study treatment.
Chronic steroid therapy, however prednisone or its equivalent is allowed at =<  mg/day.
Evidence of clinically significant immunosuppression such as the following:\r\n* Primary immunodeficiency state such as severe combined immunodeficiency disease\r\n* Concurrent opportunistic infection\r\n* Receiving systemic immunosuppressive therapy (>  weeks) including oral steroid doses >  mg/day of prednisone or equivalent within  days prior to enrollment; however, in the setting of non-immune mediated indications for steroid use, chronic/active low dose steroid use may be permitted at the discretion of the principal investigator; the dose of steroid allowed in this setting is also at the discretion of the principal investigator; (use of inhaled or topical steroids is permitted)
Patients with evidence of clinically significant immunosuppression such as the following are ineligible:\r\n* Primary immunodeficiency state such as severe combined immunodeficiency disease\r\n* Concurrent opportunistic infection\r\n* Receiving systemic immunosuppressive therapy (>  weeks) including oral steroid doses >  mg/day of prednisone or equivalent within  months prior to enrollment
Chronic steroid dependency (prednisone equivalent >  mg/day); any steroid use should be discontinued at least  weeks prior to initiation of study treatment
Evidence of clinically significant immunosuppression such as the following:\r\n* Primary immunodeficiency state such as severe combined immunodeficiency disease\r\n* HIV positive \r\n* Receiving systemic immunosuppressive therapy (>  weeks) including oral steroid doses >  mg/day of prednisone or equivalent within  months prior to enrollment\r\n* Concurrent opportunistic infection
Evidence of clinically significant immunosuppression such as the following:\r\n* Primary immunodeficiency state such as severe combined immunodeficiency disease\r\n* Concurrent opportunistic infection\r\n* Receiving systemic immunosuppressive therapy (>  weeks) including oral steroid doses >  mg/day of prednisone or equivalent within  days prior to enrollment; however, in the setting of non-immune mediated indications for use, chronic/active low dose steroid use may be permitted at the discretion of the principal investigator
Is receiving high dose systemic steroid therapy within  days of trial treatment; topical and intra-articular steroid injections are allowed, as are physiologic doses of systemic steroids (=<  mg of prednisone equivalent daily)
Participant may be receiving steroid therapy at time of enrollment (stable dose of ?  mg/day of dexamethasone or steroid equivalent).
Concurrent systemic steroid therapy higher than physiologic dose (> . mg/day of prednisone or equivalent)
Primary immunodeficiency and need for chronic steroid therapy, exception: patients on chronic physiological dose of steroid equivalent to prednisone <  mg/day is allowed
Have received systemic corticosteroids (used in the management of cancer or non-cancer-related illnesses) within one week prior to first dose; Note: systemic steroid therapy is allowed for subjects on replacement therapy as long as prednisone =<  mg or its steroid equivalent, and those patients should continue at the same dose through the trial
Primary immunodeficiency and need for chronic steroid therapy, however prednisone is allowed at <  mg/day (Turnstile I)
Receiving systemic steroids exceeding  mg prednisone or equivalent, or unstable on steroid medication, during the  weeks immediately preceding enrollment
Chronic systemic steroid therapy defined as prednisone or equivalent  mg/day or greater;
Evidence of clinically significant immunosuppression such as the following:\r\n* Primary immunodeficiency state such as severe combined immunodeficiency disease\r\n* Receiving systemic immunosuppressive therapy including prednisone >  mg per day (or equivalent), tacrolimus, everolimus, sirolimus, mycophenolate mofetil, etanercept, infliximab, etc. \r\n* Recipients of solid organ, bone marrow, or stem cell transplants; auto transplant recipients are allowed\r\n* Notes: Oral steroid doses =<  mg/day of prednisone (or equivalent) are not considered immunosuppressive and are permitted; inhaled and intraarticular corticosteroids are permitted
Steroid use equivalent to greater than  mg of prednisone within  weeks ( days) prior to Day .
Chronic oral or systemic steroid medication use at a dose of >  mg/d of prednisone or equivalent (steroids with low systemic absorption [e.g. triamcinolone hexacetonide] injected into joint space are allowed)
Concurrent steroid use of more than an equivalent of  mg/day prednisone (or equivalent)
Patients requiring chronic treatment with systemic steroid therapy, other than replacement dose steroids or treatment with low, stable dose of steroid (< mg/day prednisone or equivalent) for stable CNS metastatic disease.
Patients requiring concurrent systemic steroid therapy higher than physiologic dose (. mg/day of prednisone).
Use of a systemic steroid (>  mg prednisone daily or equivalent) =<  weeks prior to registration
Patients requiring concurrent systemic steroid therapy higher than physiologic dosage (>mg/day of prednisone or equivalent).
Dexamethasone (or equivalent systemic steroid) higher than the physiologic dosing with  days before study drug administration
Concurrent systemic steroid therapy higher than physiologic dose (> . mg/day of prednisone)
Subjects with a condition requiring systemic treatment with systemic corticosteroids (equivalent of >  mg/day of prednisone); patients may receive steroid therapy up to  days prior to starting ABVD to control lymphoma-related symptoms
Patient must not have evidence of any clinically significant immunosuppression such as the following:\r\n* Primary immunodeficiency state such as severe combined immunodeficiency disease;\r\n* Concurrent opportunistic infection;\r\n* Receiving systemic immunosuppressive therapy (>  weeks) including oral steroid doses >  mg/day of prednisone or equivalent within  months prior to enrollment
Patients using >=  mg/day of prednisone (or steroid equivalent dose) for any chronic medical condition
Systemic steroid therapy or any immunosuppressive therapy (?mg/day prednisone or equivalent).